X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ONC-841
Therapeutic Area: Oncology Product Name: ONC-841
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody candidate jointly developed by BioNTech and OncoC4. BNT316/ONC-392 is currently in late-stage clinical development in combination with lutetium (177Lu) vipivotide tetraxetan in patients with mCRPC.
Lead Product(s): Gotistobart,Lutetium Vipivotide Tetraxetan
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody, which is investigated for the treatment of metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment.
Lead Product(s): Gotistobart
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Under the collaboration BioNTech will receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 (gotistobart), as monotherapy or combination therapy in various cancer indications.
Lead Product(s): Gotistobart,Docetaxel
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration March 20, 2023
Details:
ONC-392 is the first known acid pH-sensitive anti-CTLA-4 mAb that interacts strongly with CTLA-4 at a pH typical of normal tissues/organs and the tumor microenvironment.
Lead Product(s): Onc-392,Pembrolizumab
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
ONC-392, Company’s next-gen anti-CTLA-4 monoclonal antibody (mAb) that preserves the CTLA-4 immune checkpoint function, as a single agent for the treatment of patients with metastatic NSCLC who have had disease progression on prior anti-PD-(L)1 therapy.
Lead Product(s): Onc-392
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The data signify that ONC-392 monotherapy has promising anti-tumor activity in Stage IV cancer patients who had previously failed multiple lines of therapy and who had previously acquired resistance to PD(L)1 therapy.
Lead Product(s): Onc-392,Pembrolizumab
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
